
Quarterly ResultMay 12, 2026, 08:07 AM
PMV Pharmaceuticals Q1 Net Loss $(18.0)M; Cash $93.5M
AI Summary
PMV Pharmaceuticals reported a net loss of $18.0 million for the first quarter of 2026, an increase from $17.4 million in the prior year's quarter. The company's cash, cash equivalents, and marketable securities totaled $93.5 million as of March 31, 2026. While total operating expenses decreased to $19.0 million, net cash used in operating activities rose to $19.7 million. The company expects to incur substantial additional operating losses and will need further financing.
Key Highlights
- Net loss for Q1 2026 was $(18.0) million, compared to $(17.4) million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $93.5 million as of March 31, 2026.
- Total operating expenses decreased to $19.0 million in Q1 2026 from $21.6 million in Q1 2025.
- Research and development expenses were $15.3 million, down from $17.4 million year-over-year.
- Net cash used in operating activities increased to $(19.7) million from $(18.3) million.
- Net loss per share remained at $(0.34) for both Q1 2026 and Q1 2025.
- Accumulated deficit reached $(464.5) million as of March 31, 2026.
- A $24,000 net gain was recognized from the termination of the 311 Pennington Sublease.
Price Impact
More from PMVP